HGSI Profile:
"...HGSI discovers, develops, manufactures, and sells their own genomics-based drugs. HGSI has five drugs in clinical trials, two with multiple indications. Results from up to six Phase I/II and Phase II trials could be presented in 2001. HGSI also has over $1.5 billion in cash.
In 1993,HGSI licensed to SmithKline Beecham Corp. exclusive rights to their database. Starting in July 2001, HGSI will regain full rights to their database and to technologies and intellectual property that their partners are not actively developing. At that time, HGSI will be able to enter into new large partnerships in all fields, including small molecule drug discovery and development, therapeutic proteins, antibodies, diagnostic tests, and gene therapy.
HGSI has 160 patents on human gene-based inventions, and has filed over 7,500 applications. The upcoming announcement by Celera of the number of human genes is positive news, as the current patent portfolio becomes even more valuable. (HGSI's patents will represent a greater fraction of the total number of genes.).." |
